IRON OVERDOSE IN PREGNANCY

View printable version
(Date of issue: April 2018, Version: 2.1)

This is a UKTIS monograph for use by health care professionals. For case-specific advice please contact UKTIS on 0344 892 0909. To report an exposure please download and complete a pregnancy reporting form. Please encourage all women to complete an online reporting form.

Summary

Iron is an essential mineral and is necessary for the formation of red blood cells. Iron requirements increase during pregnancy and the use of iron supplements is common, particularly in the second and third trimesters. What constitutes an iron overdose may vary, as for most drugs the risk of toxicity is calculated on a mg/kg bodyweight basis, however for the purpose of this document iron overdose is defined as ingestion of iron in excess of the recommended daily dose, or where maternal symptoms or serum iron concentration indicate toxicity.

Published data and data collected by UKTIS on iron overdose in pregnancy are limited to case reports and small case series amounting to <100 exposed pregnancies, with the majority of exposures occurring after the first trimester. The very limited data from around 20 cases of first trimester iron overdose do not provide any signal of structural teratogenesis but are too limited to perform an accurate assessment of risk of malformation. 

Maternal toxicity is likely to be a major predictor of fetal outcome. There are currently no published guidelines on the treatment of iron overdose in pregnancy. Iron overdose can be fatal, therefore treatment of the mother should be as for the non-pregnant patient. Desferrioxamine, when indicated, should not be withheld on account of the pregnancy. For current UK guidelines regarding treatment of iron overdose please refer to TOXBASE. There are no epidemiological studies reporting on rates of outcomes such as spontaneous abortion, stillbirth, neonatal problems, low birth weight or preterm delivery following maternal iron overdose with or without desferrioxamine treatment in pregnancy, but the limited data available suggest that timely and adequate treatment of maternal toxicity as for the non-pregnant patient mitigates against the risk of these adverse outcomes. Effects on longer term infant neurodevelopment have not been studied and many reports relate to infant outcome shortly after birth.
 
When iron overdose is associated with maternal toxicity, enhanced fetal monitoring may be warranted. The absence of maternal toxicity, however, does not exclude the possibility of adverse events and obstetric follow up should be determined on a case-by case basis.

All episodes of overdose, whether intentional or apparently accidental, should be fully documented in the maternity record. Referral to a perinatal psychiatrist should be considered in all cases of intentional iron overdose.

Discussion with UKTIS is recommended for all cases.

Please note, this document relates only to iron overdose in pregnancy and not therapeutic use of iron supplements.
                      
This document is regularly reviewed and updated. Only use full UKTIS monographs downloaded directly from TOXBASE.org to be sure you are using the most up-to-date version. The summaries of these monographs are openly available on UKTIS.org.

This is a summary of the full UKTIS monograph for health care professionals and should not be used in isolation. The full UKTIS monograph and access to any hyperlinked related documents is available to health care professionals at www.toxbase.org.

If you have a patient with exposure to a drug or chemical and require assistance in making a patient-specific risk assessment, please telephone UKTIS on 0344 892 0909 to discuss the case with a teratology specialist.

If you would like to report a pregnancy to UKTIS please click here to download our pregnancy reporting form. Please encourage all women to complete an online reporting form.

Disclaimer: Every effort has been made to ensure that this monograph was accurate and up-to-date at the time of writing, however it cannot cover every eventuality and the information providers cannot be held responsible for any adverse outcomes of the measures recommended. The final decision regarding which treatment is used for an individual patient remains the clinical responsibility of the prescriber. This material may be freely reproduced for education and not for profit purposes within the UK National Health Service, however no linking to this website or reproduction by or for commercial organisations is permitted without the express written permission of this service. This document is regularly reviewed and updated. Only use UKTIS monographs downloaded directly from TOXBASE.org or UKTIS.org to ensure you are using the most up-to-date version.